General
Preferred name
zuclopenthixol
Synonyms
CLOPENTHIXOL ()
N-746 ()
AY-62021 ()
Chlorpenthixol ()
(Z)-Clopenthixol ()
Cisordinol ()
cis-Clopenthixol ()
Zuclopenthixol hydrochloride ()
Zuclopenthixol dihydrochloride ()
Clopixol ()
Clopenthixol cis(z)-form ()
Zuclopentixol ()
Clopenthixol ()
P&D ID
PD009440
CAS
58045-23-1
63978-46-1
53772-83-1
633-59-0
Tags
available
drug
Approved by
MHRA
Drug indication
Schizophrenia
Antipsychotic
Drug Status
investigational
approved
Max Phase
3.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
TOXICITY Although there have not been any cases of overdosage reported, the symptoms are likely to be somnolence, coma, extrapyramidal symptoms, convulsions, hypotension, shock, or hyper- or hypothermia.; ; Neuroleptic malignant syndrome may occur. Zuclopenthixol may potentiate anticholinergic effects of concurrent medications. Zuclopenthixol has a demonstrated antiemetic effect in animals, and may mask signs of toxicity due to other drug overdoses, or may mask symptoms of disease.
DESCRIPTION Zuclopenthixol is a thioxanthene class typical antipsychotic. Chemically it is the cis-isomer of clopenthixol. The CAS registry number (53772-83-1) submitted with the WHO INN record for zuclopenthixol maps to PubChem CID 5311507. (GtoPdb)
DESCRIPTION Zuclopenthixol is an antagonist at D1 and D2 dopamine receptors. It also has high affinity for alpha1-adrenergic and 5-HT2 receptors, but it has weaker histamine H1 receptor blocking activity, and even lower affinity for muscarinic cholinergic and alpha2-adrenergic receptors. lt is the cis-isomer of clopenthixol. It is an antipsychotic drug belonging the thioxanthene class. It was introduced in 1962 by Lundbeck. It has been listed, but is not approved for use in the United States. (BOC Sciences Bioactive Compounds)
Compound Sets
15
BOC Sciences Bioactive Compounds
zuclopenthixol-cas-53772-83-1-item-70904
Cayman Chemical Bioactives
24961
ChEMBL Drugs
CHEMBL53904
Drug Repurposing Hub
DrugBank
DB01624
DrugBank Approved Drugs
DB01624
DrugCentral
2877
DrugCentral Approved Drugs
2877
DrugMAP
DMKYD5N
DrugMAP Approved Drugs
DMKYD5N
Guide to Pharmacology
7559
MedChem Express Bioactive Compound Library
HY-A0163
Other bioactive compounds
Prestwick Chemical Library
TargetMol Bioactive Compound Library
T4117
External IDs
43
Properties
(calculated by RDKit )
Molecular Weight
400.14
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
5
Ring Count
4
Aromatic Ring Count
2
cLogP
4.24
TPSA
26.71
Fraction CSP3
0.36
Chiral centers
0.0
Largest ring
6.0
QED
0.69
Structural alerts
1
styrene_B(8)
c:1:c:c-2:c(:c:c:1)-[#6](-c:3:c(-[$([#16;X2]),$([#6;X4])]-2):c:c:[c;!H0,$(c-[#17]),$(c-[#6;X4])](:c:3))=[#6]-[#6]
PAINS Family C
Related compounds
Custom attributes
(extracted from source data)
Pathway
GPCR/G protein
Neuroscience
Neuronal Signaling
Target
D1
D2
ADRA1A, ADRA2A, DRD1, DRD2, DRD5, HRH1, HTR2A
Dopamine Receptor
Indication
schizophrenia, bipolar disorder
MOA
Dopamine Receptor antagonist
Therapeutic Class
Antipsychotic Agents
Solubility
Benzene, Chloroform, DMSO, Ethanol, Methanol
Source data